Given that there are limited effective therapeutic options for patients with Class II and III BRAF mutations, we also conducted a comprehensive investigation of the therapeutic potential of exarafenib, a novel type 2 pan-RAF inhibitor and ATP-competitive small molecule agent20, in BRAF-mutant NSCLC. This evidence concerns the gene RAF1 and non-small cell lung carcinoma.